Opioid-use DisorderNCT04363320

Fostering MAT Use in Justice Populations

A study testing NIATx Coaching and ECHO in people with Opioid-use Disorder and Recidivism, run by University of Wisconsin, Madison at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The grant will test two timely and successful evidence-based implementation practices, NIATx Coaching and ECHO, with jail/community-based healthcare providers to increase medication assisted treatment (MAT) use with justice populations. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Opioid-use Disorder, Recidivism
What is being tested?: NIATx Coaching and ECHO
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 256 participants
Where: 1 siteUnited States
Study dates: 30 Jul 2020to 28 Feb 2024
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

None listed.

Who cannot join

Trial locations and contacts

1 site in 1 country.

United States1 site

University of Wisconsin-Madison
Madison, Wisconsin, 53706

Other trials in United States

About this study

Read the detailed description

In this trial, the investigators will test two implementation interventions being applied to medications for opioid use disorder (MOUD) dissemination and implementation in justice settings for justice-involved populations: NIATx Coaching and the Extension for Community Healthcare Outcomes (ECHO) model. NIATx Coaches provide expertise in MOUD implementation and organizational change to help treatment organizations and staff make, sustain, and spread MOUD. The ECHO platform focuses only on the provider side by connecting the primary care provider with expert MOUD prescribers to promote high-quality MOUD practices. This will be the first trial that assesses the comparative effectiveness of these approaches overall, and in justice settings.

The trial will be conducted with a combination of 48 jails and community-based organizations that treat individuals with opioid use disorders (OUDs) post-incarceration. Sites will be randomly assigned to one of four study arms, with 12 sites in each arm: High-Dose Coaching/ECHO, Low-Dose Coaching/ECHO, High-Dose Coaching/No ECHO, and Low-Dose Coaching/No ECHO. The intervention period will be over a 12-month span with an additional 12-months for sustainability.

Conditions: Opioid-use Disorder, Recidivism
Being tested: NIATx Coaching, ECHO
Keywords: MOUD, OUD, Justice Populations, Jails, ECHO, NIATx, Inter-agency
Medical subject headings: Opioid-Related Disorders, Recidivism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

NIATx CoachingBehavioural
NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.
ECHOBehavioural
Also called Extension for Community Healthcare Outcomes
The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.

Study groups in NCT04363320
Study group	Role	What they receive
High-Dose NIATx Coaching & ECHO	Experimental	* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * 12 monthly (one-hour) coaching calls with Change Leader/Team * Prescribers participate in 12 monthly (one-hour) scheduled video conference calls Receives: Behavioral: NIATx Coaching; Behavioral: ECHO
Low-Dose NIATx Coaching & ECHO	Experimental	* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * Four (one-hour) coaching calls at months 1, 4, 8, and 12 with Change Leader/Team * Prescribers participate in 12 monthly (one-hour) scheduled video conference calls Receives: Behavioral: NIATx Coaching; Behavioral: ECHO
High-Dose NIATx Coaching & No ECHO	Experimental	* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * 12 monthly (one-hour) coaching calls with Change Leader/Team Receives: Behavioral: NIATx Coaching
Low-Dose NIATx Coaching & No ECHO	Experimental	* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * Four (one-hour) coaching calls at months 1, 4, 8, and 12 with Change Leader/Team Receives: Behavioral: NIATx Coaching

What is being measured

The primary outcome is the main question the study is designed to answer.

Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Intervention Phase
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Measured: baseline to 12 months
Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Sustainability Phase
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Measured: 13 months, 24 months
Mean Total Number of Eligible Justice Involved Persons on MOUD Per Month: Intervention Phase
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Measured: baseline to 12 months
Mean Total Number of Eligible Justice Involved Persons on MOUD Per Month: Sustainability Phase
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Measured: 13 months to 24 months
Change in Number of Prescribers Using MOUD
The adoption of each intervention will be in part measured by tracking the number of prescribers using MOUD at each time point.
Measured: baseline, 12 months, 24 months

Secondary outcomes (1)

MOUD Sustainability Measured Using the Program Sustainability Assessment Tool
The maintenance of the intervention (MOUD Sustainability) will be measured using the Program Sustainability Assessment Tool included in the Staff Survey at three points during the study (baseline, 12-months \& 24-months) to determine if likelihood of sustainability increases as study progresses. This tool has a total possible range of scores from 0-63 with higher scores indicating increased sustainability of the intervention.
Measured: baseline, 12 months, 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Jul 202028 Feb 2024

First posted27 Apr 2020
Study start30 Jul 2020
Primary completion28 Feb 2024
Study completion28 Feb 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Opioid-use DisorderStudies of the same condition, open and under way.
More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Health services research
Allocation: Randomised
Intervention model: Factorial
Model description: The proposed study will implement a cluster randomized block design where staff are nested within sites. The community-based provider sites and jails will be grouped into homogeneous blocks and then randomly assigned into 2x2 factorial design for each block. The forty-eights sites will be assigned to one of four study arms using a matching strategy within the blocks that groups four jail-clinic combination together prior to randomization. Each jail and cognitive behavioral (CB) treatment provider (or clinic) in these combinations will be treated as a site.
Masking: None (open label)
Enrolment: 256 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04363320
Sponsor's protocol ID: 2019-1473
Other IDs: 3U2CDA050097-01S1, 20200548, A195010, ENGR/CHESS PROGRAM
Status last verified: May 2025
First submitted: 23 Apr 2020
Last updated: 28 May 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Publications

Molfenter T, Vechinski J, Kim JS, Zhang J, Meng L, Tveit J, Madden L, Taxman FS. Assessing the comparative effectiveness of ECHO and coaching implementation strategies in a jail/provider MOUD implementation trial. Implement Sci. 2025 Feb 3;20(1):7. doi: 10.1186/s13012-025-01419-6.
PubMed 39901259

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse

All Opioid-use Disorder trials

Study at a glance

From the registry record, last updated by the sponsor on 28 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Fostering MAT Use in Justice Populations
ClinicalTrials.gov ID: NCT04363320
Acronym / sponsor ID: 2019-1473
Conditions: Opioid-use Disorder, Recidivism
Keywords: MOUD, OUD, Justice Populations, Jails, ECHO, NIATx, Inter-agency
Study type: Interventional
Recruitment status: Completed
Enrolment: 256 participants (actual)
Lead sponsor: University of Wisconsin, MadisonUniversity, hospital or other
Collaborators: George Mason University, National Institute on Drug Abuse (NIDA)
Study start: 30 Jul 2020 (actual)
Primary completion: 28 Feb 2024 (actual)
Study completion: 28 Feb 2024 (actual)
First posted: 27 Apr 2020 (actual)
Results: Posted 28 May 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Health services research
Allocation: Randomised
Intervention model: Factorial
Masking: None (open label)
Number of arms: 4
Model description: The proposed study will implement a cluster randomized block design where staff are nested within sites. The community-based provider sites and jails will be grouped into homogeneous blocks and then randomly assigned into 2x2 factorial design for each block. The forty-eights sites will be assigned to one of four study arms using a matching strategy within the blocks that groups four jail-clinic combination together prior to randomization. Each jail and cognitive behavioral (CB) treatment provider (or clinic) in these combinations will be treated as a site.

Arm	Type	Receives
High-Dose NIATx Coaching & ECHO	Experimental	Behavioral: NIATx Coaching, Behavioral: ECHO* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * 12 monthly (one-hour) coaching calls with Change Leader/Team * Prescribers participate in 12 monthly (one-hour) scheduled video conference calls
Low-Dose NIATx Coaching & ECHO	Experimental	Behavioral: NIATx Coaching, Behavioral: ECHO* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * Four (one-hour) coaching calls at months 1, 4, 8, and 12 with Change Leader/Team * Prescribers participate in 12 monthly (one-hour) scheduled video conference calls
High-Dose NIATx Coaching & No ECHO	Experimental	Behavioral: NIATx Coaching* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * 12 monthly (one-hour) coaching calls with Change Leader/Team
Low-Dose NIATx Coaching & No ECHO	Experimental	Behavioral: NIATx Coaching* Four-hour, Virtual Kick-Off Meeting split into two days with Study Team \& Coaches * Four (one-hour) coaching calls at months 1, 4, 8, and 12 with Change Leader/Team

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (0 listed)

Key exclusion criteria (1 listed)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
NIATx CoachingNIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.	Behavioural	High-Dose NIATx Coaching & ECHO, High-Dose NIATx Coaching & No ECHO, Low-Dose NIATx Coaching & ECHO, Low-Dose NIATx Coaching & No ECHO
ECHOAlso: Extension for Community Healthcare OutcomesThe ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.	Behavioural	High-Dose NIATx Coaching & ECHO, Low-Dose NIATx Coaching & ECHO

Primary outcome

Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Intervention Phase
Time frame: baseline to 12 months
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Sustainability Phase
Time frame: 13 months, 24 months
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Mean Total Number of Eligible Justice Involved Persons on MOUD Per Month: Intervention Phase
Time frame: baseline to 12 months
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Mean Total Number of Eligible Justice Involved Persons on MOUD Per Month: Sustainability Phase
Time frame: 13 months to 24 months
The intervention reach will be measured using data gathered through organization monthly tracking sheets to track MOUD use. 'Involved persons' include those who are initiated onto any MOUD (buprenorphine, extended-release injectable naltrexone, or methadone) and engaged with MOUD use.
Change in Number of Prescribers Using MOUD
Time frame: baseline, 12 months, 24 months
The adoption of each intervention will be in part measured by tracking the number of prescribers using MOUD at each time point.

1 secondary outcome

MOUD Sustainability Measured Using the Program Sustainability Assessment Tool
Time frame: baseline, 12 months, 24 months

Results and safety

Results posted to the registry on 28 May 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
High-Dose NIATx Coaching & ECHO	78	35
Low-Dose NIATx Coaching & ECHO	65	23
High-Dose NIATx Coaching & No ECHO	60	35
Low-Dose NIATx Coaching & No ECHO	53	24

Primary outcome: Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Intervention Phase

Time frame: baseline to 12 months. Mean (Standard Deviation). Unit: New Justice Involved Persons per month

Measure	High-Dose NIATx Coaching & ECHO n = 4572	Low-Dose NIATx Coaching & ECHO n = 256	High-Dose NIATx Coaching & No ECHO n = 569	Low-Dose NIATx Coaching & No ECHO n = 1908
Methadone	20.36 (51.31)	0.55 (1.57)	4.47 (9.63)	2.03 (5.57)
Buprenorphine	21.79 (28.5)	3.00 (4.05)	5.01 (2.98)	17.43 (25.56)
Naltrexone	0.19 (0.28)	0.33 (0.42)	0.44 (0.86)	1.37 (2.05)

High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: 0.538, p = 0.002, Mixed Models Analysis
High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: 0.38, p = 0.0008, Mixed Models Analysis
High-Dose NIATx Coaching & No ECHO: Slope: 0.207, p = 0.111, Mixed Models Analysis

Population analysed: The Overall Number of Participants Analyzed reported are justice involved individuals staff (who were not consented and enrolled). Staff (consented participants) collected counts of justice involved individuals with various MOUD from their sites. Not all sites provided all three forms of medication at all times. Due to lack of tracking systems in the jail, some sites were only able to provide one of the two monthly counts.

Primary outcome: Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Sustainability Phase

Time frame: 13 months, 24 months. Mean (Standard Deviation). Unit: New Justice Involved Persons per month

Measure	High-Dose NIATx Coaching & ECHO n = 6345	Low-Dose NIATx Coaching & ECHO n = 240	High-Dose NIATx Coaching & No ECHO n = 542	Low-Dose NIATx Coaching & No ECHO n = 3022
Methadone	28.29 (75.24)	0.01 (0.03)	4.67 (6.6)	2.41 (6.31)
Buprenorphine	30.37 (35.77)	3.3 (4.4)	7.89 (3.18)	32.32 (60.72)
Naltrexone	0.09 (0.13)	1.32 (1.59)	0.71 (0.79)	0.79 (1.01)

High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: 0.153, p = 0.485, Mixed Models Analysis
High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: 0.642, p = 0.0008, Mixed Models Analysis
High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: -0.377, p = 0.015, Mixed Models Analysis

Primary outcome: Mean Total Number of Eligible Justice Involved Persons on MOUD Per Month: Intervention Phase

Time frame: baseline to 12 months. Mean (Standard Deviation). Unit: Justice Involved Persons per month

Measure	High-Dose NIATx Coaching & ECHO n = 19120	Low-Dose NIATx Coaching & ECHO n = 8588	High-Dose NIATx Coaching & No ECHO n = 9025	Low-Dose NIATx Coaching & No ECHO n = 6263
Methadone	98.73 (216.36)	0.08 (0.35)	56.58 (158.40)	0.94 (1.80)
Buprenorphine	104.07 (145.32)	117.62 (190.42)	36.50 (45.29)	60.57 (105.31)
Naltrexone	0.24 (0.34)	2.60 (5.29)	5.81 (15.04)	3.21 (6.16)

High-Dose NIATx Coaching & ECHO: Slope: 1.912, p = 0.00002, Mixed Models Analysis
Low-Dose NIATx Coaching & ECHO: Slope: 0.855, p = 0.00004, Mixed Models Analysis
High-Dose NIATx Coaching & No ECHO: Slope: 0.322, p = 0.118, Mixed Models Analysis

Primary outcome: Mean Total Number of Eligible Justice Involved Persons on MOUD Per Month: Sustainability Phase

Time frame: 13 months to 24 months. Mean (Standard Deviation). Unit: Justice Involved Persons per month

Measure	High-Dose NIATx Coaching & ECHO n = 24145	Low-Dose NIATx Coaching & ECHO n = 5799	High-Dose NIATx Coaching & No ECHO n = 9489	Low-Dose NIATx Coaching & No ECHO n = 8041
Methadone	110.19 (219.28)	0.01 (0.03)	77.22 (183.37)	1.96 (3.71)
Buprenorphine	127.32 (177.17)	154.78 (227.42)	43.71 (43.31)	78.24 (136.17)
Naltrexone	0.22 (0.31)	1.67 (1.56)	10.86 (18.72)	3.7 (6.44)

High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: 0.617, p = 0.045, Mixed Models Analysis
High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: 1.103, p = 0.000002, Mixed Models Analysis
High-Dose NIATx Coaching & ECHO vs Low-Dose NIATx Coaching & ECHO vs High-Dose NIATx Coaching & No ECHO vs Low-Dose NIATx Coaching & No ECHO: Slope: -0.387, p = 0.076, Mixed Models Analysis

1 secondary outcome is reported in the full results.

Adverse events

Time frame: up to 24 months. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
High-Dose NIATx Coaching & ECHO	0 of 78 (0%)	0 of 78 (0%)	0 of 78
Low-Dose NIATx Coaching & ECHO	0 of 65 (0%)	0 of 65 (0%)	0 of 65
High-Dose NIATx Coaching & No ECHO	0 of 60 (0%)	0 of 60 (0%)	1 of 60
Low-Dose NIATx Coaching & No ECHO	0 of 53 (0%)	0 of 53 (0%)	0 of 53

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Results publication: PubMed 39901259Molfenter T, Vechinski J, Kim JS, Zhang J, Meng L, Tveit J, Madden L, Taxman FS. Assessing the comparative effectiveness of ECHO and coaching implementation strategies in a jail/provider MOUD implementation trial. Implement Sci. 2025 Feb 3;20(1):7. doi: 10.1186/s13012-025-01419-6.
Individual participant dataSharing planned: No

Related trials for Opioid-use Disorder

Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Todd Molfenter, PhD principal investigator

University of Wisconsin, Madison

Faye Taxman, PhD principal investigator

George Mason University

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing NIATx Coaching and ECHO in people with Opioid-use Disorder and Recidivism, run by University of Wisconsin, Madison at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 May 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Number of New Eligible Justice Involved Persons Initiated With MOUD Per Month: Intervention Phase (time frame: baseline to 12 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04363320, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2025.